PROM1 and pancreatic neoplasm: Treating cells with Rapamycin, a specific inhibitor of mTOR, showed a decrease in the proliferation and viability of the entire glial cell populations, including stem/progenitor cells: the percentage of CD133+ cells remained after treatment in pancreatic cancers [35].